aea004

Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street
BLSB 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
  2. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
  3. Novel therapeutic strategies and targets in advanced uveal melanoma
  4. CKS1 expression in melanocytic nevi and melanoma
  5. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  6. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
  7. “If you want to go far, go together”
  8. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  9. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klotho
  10. Dysregulated GPCR signaling and therapeutic options in uveal melanoma
  11. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  12. Running INTERFERONce on immunotherapy
  13. The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells
  14. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
  15. Triple jeopardy for people with albinism
  16. The melanoma field with dendritic roots
  17. The state of melanoma: challenges and opportunities
  18. Targeting mutant NRAS signaling pathways in melanoma
  19. Of Mice and melanoma: PDX system for modeling personalized medicine
  20. Welcome to the New Year!